Insulet Corporation $PODD Shares Bought by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale raised its holdings in Insulet Corporation (NASDAQ:PODD) by 1.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,720 shares of the medical instruments supplier’s stock after purchasing an additional 113 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Insulet were worth $3,662,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Sequoia Financial Advisors LLC grew its holdings in Insulet by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 2,017 shares of the medical instruments supplier’s stock valued at $634,000 after purchasing an additional 45 shares during the period. Nissay Asset Management Corp Japan ADV grew its holdings in Insulet by 0.6% in the first quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock valued at $2,222,000 after purchasing an additional 48 shares during the period. Mather Group LLC. grew its holdings in Insulet by 4.4% in the second quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock valued at $360,000 after purchasing an additional 48 shares during the period. Brooklyn Investment Group boosted its stake in shares of Insulet by 7.0% in the first quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock worth $209,000 after acquiring an additional 52 shares during the last quarter. Finally, Cooper Financial Group boosted its stake in shares of Insulet by 5.7% in the first quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier’s stock worth $283,000 after acquiring an additional 58 shares during the last quarter.

Insider Activity

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Insulet Price Performance

PODD opened at $320.91 on Friday. The stock has a fifty day moving average of $327.60 and a 200-day moving average of $304.83. The firm has a market capitalization of $22.59 billion, a P/E ratio of 97.54, a PEG ratio of 2.68 and a beta of 1.40. Insulet Corporation has a 12-month low of $226.50 and a 12-month high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same period in the prior year, the business posted $0.55 earnings per share. Insulet’s revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts forecast that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on PODD shares. Leerink Partners lifted their target price on Insulet from $339.00 to $355.00 and gave the company an “outperform” rating in a research report on Tuesday, October 14th. The Goldman Sachs Group lowered their price objective on Insulet from $399.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. Royal Bank Of Canada upped their price objective on Insulet from $350.00 to $365.00 and gave the stock an “outperform” rating in a research report on Friday, October 10th. Citigroup reissued a “buy” rating on shares of Insulet in a report on Tuesday, July 8th. Finally, Stifel Nicolaus initiated coverage on Insulet in a research note on Tuesday, October 21st. They set a “buy” rating and a $370.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $352.11.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.